CHF Solutions, Inc. to Present Healthcare Cost Analysis of Aquadex FlexFlow System Compared to Standard of Care in Heart Fail...
April 26 2018 - 8:30AM
CHF Solutions, Inc. (Nasdaq:CHFS) announces today that new
comparative data between the company’s Aquadex FlexFlow system and
pharmaceutical therapy will be presented in a poster session at the
International Society for Pharmacoeconomics and Outcomes Research
(ISPOR) conference.
The poster, titled “Ultrafiltration vs. Diuretics for the
Treatment of Fluid Overload in Heart Failure Patients: A Hospital
Cost Analysis,” will be presented on Wednesday, May 23, 2018 at the
Baltimore Convention Center, Baltimore, Md.
“We have long established the viability of ultrafiltration
therapy through both robust clinical evidence and customer
experience,” said John Erb, chairman and chief executive officer of
CHF Solutions. "We are pleased to be presenting these data at
the ISPOR conference, which will provide additional evidence for
physicians to consider when choosing a therapy for fluid overloaded
heart failure patients.” About CHF
Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device
company focused on commercializing the Aquadex FlexFlow system for
Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for
temporary (up to eight hours) ultrafiltration treatment of patients
with fluid overload who have failed diuretic therapy, and extended
(longer than 8 hours) ultrafiltration treatment of patients with
fluid overload who have failed diuretic therapy and require
hospitalization. All treatments must be administered by a
healthcare provider, under physician prescription, both of whom
having received training in extracorporeal therapies. The company's
mission is to predict, measure, and control patient fluid balance
through science, collaboration, and innovative medical
technology. CHF Solutions is a Delaware corporation
headquartered in Minneapolis, Minnesota with wholly owned
subsidiaries in Australia and Ireland. The company
has been listed on the NASDAQ Capital Market since February
2012.
CONTACTS:
INVESTORS: Claudia Napal Drayton Chief
Financial Officer CHF Solutions, Inc. 952-345-4205
ir@chf-solutions.com
-or- Bret Shapiro Managing Partner CORE IR 516-222-2560
brets@coreir.com www.coreir.com
MEDIA Jules Abraham JQA Partners, Inc.
917-885-7378 jabraham@jqapartners.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024